<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039740</url>
  </required_header>
  <id_info>
    <org_study_id>2007-08-092</org_study_id>
    <nct_id>NCT01039740</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Study of Mirtazapine Response in Depressed Patients</brief_title>
  <official_title>Pharmacogenetic Study of Mirtazapine Response in Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pharmacogenetic study predict Mirtazapine
      responsiveness in advance before the appearance of the drug effect until 4-6 weeks after
      administration of Mirtazapine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is

        1. to determine whether genomic differences between drug responders and nonresponders
           predict the response of Mirtazapine and

        2. to construct the prediction model for Mirtazapine treatment in depressed patients in
           order to aid to select the genetically matching drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mirtazapine response at 2,4,6 weeks and adverse events (A/E) monitoring at 1,2,4,6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological value at 0 and 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Responders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-responders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Mirtazapine administration for 6 weeks under therapeutic dose</description>
    <arm_group_label>Responders</arm_group_label>
    <arm_group_label>Non-responders</arm_group_label>
    <other_name>Mirtazapine_Remeron, Avanza, Zispin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical
             Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a
             semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The
             affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the
             Korean version of the structured clinical interview for the diagnostic and statistical
             manual of mental disorders, Fourth edition.

          2. interview with one more patient's family member for objective diagnosis and final
             diagnosis decision by agreements of two more psychiatric physicians

        Exclusion Criteria:

          1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4
             weeks

          2. potential study participants for pregnancy, significant medical conditions, abnormal
             laboratory baseline values, unstable psychiatric features(eg.suicidal), history of
             alcohol of drug dependence, seizures, head trauma with loss of consciousness,
             neurological illness, or concomitant Axis I psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JungShil Back, B/Sc.</last_name>
    <phone>82-2-3410-0946</phone>
    <email>junshil.back@sbri.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shinn-won Lim, M.Sc.</last_name>
    <phone>82-2-3410-3759</phone>
    <email>shinwon.lim@sbri.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samsung Medical Center Kim, phD, MD</last_name>
      <phone>82-2-3410-3582</phone>
      <email>dohkwan.kim@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2009</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Prediction of Mirtazapine response</keyword>
  <keyword>Depressed patients</keyword>
  <keyword>Mirtazapine response</keyword>
  <keyword>Adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

